Skip to main content
. Author manuscript; available in PMC: 2016 May 24.
Published in final edited form as: Neurocrit Care. 2014 Dec;21(3):476–482. doi: 10.1007/s12028-014-9974-y

Table 3.

Clinical predictors of poor outcome

Patient characteristic Good outcome (mRS 0–3) n = 21 Poor outcome (mRS 4–6) n = 48 Univariate OR [95 % CI] Multivariate OR [95 % CI]
Demographics
 Age > median, n (%) 8 (38.1 %) 28 (58.3 %) 2.3 [0.80–6.51] 2.0 [0.50–8.01]
Clinical presentation
 High grade (HH 4–5), n (%) 1 (5.0 %) 24 (52.2 %) 20.7 [2.56–168.0]** 13.3 [1.58–350.0]**
 Thick cisternal blood (F 3), n (%) 19 (90.5 %) 32 (66.0 %) 0.2 [0.04–1.02]* 0.6 [0.02–8.22]
 Intraparenchymal hemorrhage, n (%) 4 (19.1 %) 11 (23.4 %) 1.3 [0.36–4.68]
 Intraventricular hemorrhage, n (%) 15 (71.4 %) 33 (68.8 %) 0.9 [0.29–2.71]
 Hydrocephalus, n (%) 11 (52.4 %) 27 (56.3 %) 1.2 [0.42–3.27]
 MCA aneurysm location, n (%) 1 (4.8 %) 7 (14.6 %) 3.4 [0.40–29.68]
 ACA aneurysm location, n (%) 1 (4.8 %) 4 (8.3 %) 1.8 [0.19–17.32]
 Craniotomy, n (%) 15 (71.4 %) 30 (62.5 %) 0.7 [0.22–2.03]
 Clinical suspicion for seizure, n (%) 3 (14.3 %) 28 (58.3 %) 8.4 [2.17–32.41]** 3.9 [0.87–21.36]
Electrophysiology
 Seizure at ictus, n (%) 1 (5.6 %) 10 (21.7 %) 4.7 [0.56–39.9]
 Receiving AED, n (%) 10 (47.6 %) 28 (58.3 %) 1.6 [0.55–4.32]
 EEG evidence of seizure, n (%) 1 (4.8 %) 7 (14.6 %) 3.4 [0.39–29.68]

MCA middle cerebral artery, ACA anterior cerebral artery, AED anti-epileptic drug

*

p ≤ 0.05,

**

p ≤ 0.01